Has Jennifer Lim, MD received payments from drug or device companies?

Yes. Drug and device makers reported $150,086 in general payments to Jennifer Lim, MD across 110 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jennifer Lim, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jennifer Lim, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jennifer Lim, MD

Ophthalmology · Chicago, ILNPI 1386706182

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $130,708 of the $150,086 with a category attached, or 87.1%. It is spread thinly across 22 manufacturers, the largest accounting for just 23.1%. Reporting peaked in 2023 at $46,510 and has fallen 52.9% since, to $21,922 in 2025. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$150,086in general payments, 2019–2025

Across 110 payments — averaging $1364.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

F. Hoffmann-la Roche AG$35K
Genentech USA, Inc.$23K
Novartis$17K
Regeneron$16K
AbbVie$14K
Genentech, Inc.$13K
plus $32K from 16 others

$556,787in research payments, 2019–2025

Across 148 payments — averaging $3762.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$241K
Regeneron$171K
F. Hoffmann-la Roche AG$60K
Ocular Therapeutix, Inc.$60K
Janssen Research & Development, LLC$25K

What the payments were for

Consulting fees$130,70887%
Speaking & faculty fees$14,61010%
Travel & lodging$1,9811%
Food & beverage$2,7872%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
F. Hoffmann-la Roche AG	18	$34,630
Genentech USA, Inc.	13	$22,692
Novartis	6	$16,947
Regeneron	13	$16,234
AbbVie(2 entities)	13	$14,285
Genentech, Inc.	13	$13,128
Boehringer Ingelheim	3	$8,550
Eyepoint US, Inc.	7	$6,220
Hexal AG	2	$5,913
Apellis Pharmaceuticals, Inc.	6	$4,490
Bausch & Lomb, A Division Of Bausch Health US, LLC	2	$2,500
Bausch & Lomb Americas Inc.	2	$2,000
Ocular Therapeutix, Inc.	1	$1,910
Cardinal Health 110 LLC	1	$150
E.r. Squibb & Sons, L.L.C.	1	$125
Johnson & Johnson	1	$110
Regeneron Healthcare Solutions, Inc.	3	$84
Alimera Sciences, Inc.	1	$30
Carl Zeiss Meditec, Inc.	1	$29
Glaukos Corporation	1	$26
Sanofi Pasteur Inc.	1	$21
Journey Medical Corporation	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VABYSMO$23,209
ADAKVEO$10,481
Lucentis$10,365
EYLEA$7,539
Non-Covered Product$6,763
EYP-1901$6,150
VEOPOZ$4,700
Syfovre$4,257
EYLEA HD$4,129
SUSVIMO$4,121
PROLENSA$3,500
LOTEMAX$2,500
CRYSTALENS$2,500
ENVISTA$2,500
VICTUS$2,500
BEOVU$2,150
VISUDYNE$2,000
RETISERT$2,000
OZURDEX$1,500
LOTEMAX SM$1,000

How this compares

$150,086 in reported general payments places this provider in the 95th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois →

Medicare billing

Part B allowed, 2024

$133,752

Medicare patients

385

Services billed

1,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	28	$1,013
Ketorolac Tromethamine	25	$304

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Chicago

Seenu HariprasadChicago$2.3M
Yannek LeidermanChicago$312K
Asim FarooqChicago$270K
Dilraj GrewalChicago$188K
Ahmad ArefChicago$179K
Robert SchroederChicago$153K
Surendra BastiChicago$126K
Allen PuttermanChicago$94K
Maria CortinaChicago$88K
Robison ChanChicago$81K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →